OBR Daily Commentary

forumImage

Robert Comis, Piano Man, Clinical Trials Impresario, and ECOG-ACRIN Co-chair, Dies Unexpectedly at 71

(The Cancer Letter) May 12, 2017 - It’s possible that there were pianos that Bob Comis didn’t like. The luminary of clinical trials commandeered pianos wherever he found them—at hotel lounges and at the American Society of Clinical Oncology president’s receptions, where, year after year, he blasted his way through My Way.

Read Article arrow

Howard S. Hochster, MD (Posted: May 15, 2017)

quotesDr Bob Comis was a stolid and long-term leader of the old cooperative group system. He helped lead the transformation to the new NCTN. We will miss his guidance and wisdom. A real loss for our community.quotes

Add Comment 1 Comment
forumImage

AbbVie Announces Topline Results from Two Phase 3 Studies Investigating Veliparib in Combination with Chemotherapy for the Treatment of Patients with Advanced or Metastatic Squamous Non-Small Cell Lung Cancer and Early-Stage Triple-Negative Breast Cancer

(AbbVie) Apr 19, 2017 - AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primary endpoints.

Read Article arrow

Howard S. Hochster, MD (Posted: April 27, 2017)

quotesIt is not difficult to imagine that PARP inhibitors, which function through the Homologous Repair pathway, would not add much to standard platinum based therapy in unselected lung cancer and TNBC. What is harder to imagine, is what AbbVie would launch phase 3 trials in unselected patient populations who do not have defined DNA repair defects. We can do better in this era of tumor profiling.quotes

Add Comment 2 Comment
forumImage

Supreme Court to Review Biosimilar Battle Between Amgen and Sandoz

(STAT Plus/Pharmalot) Apr 25, 2017 - A hotly anticipated hearing takes place at the US Supreme Court on Wednesday about biosimilars and the eventual decision is expected to have widespread implications for health care costs.

Read Article arrow

Howard S. Hochster, MD (Posted: April 26, 2017)

quotesFascinating legal wrangling as the Supremes parse the wording of the BPCIA (Biologic Price Competition and Innovation Act). At stake, whether the biosimilar manufacturer must supply the originator company with a copy of their BLA application, and whether an additional 180 day waiting period Is required following actual FDA approval of the biosimilar for the originator to issue patent litigation. This would invalidate notification prior to the formal licensure. Who knew biosimilars could be so exciting and reach SCOTUS ??quotes

Add Comment 1 Comment

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...